Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
8 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
SHELTON, CT / / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment for Monkeypox Virus Infection has begun with enrollment of first…
NNVC - Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
SHELTON, CT / / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo E…
NanoViricides (NNVC) said its Phase II clinical trial of NV-387 oral gummies to treat the current Bundibugyo Ebola outbreak has been registered in the Pan African Clinical Trials Database and is ready to go.
NNVC says a Phase II clinical trial of NV-387 oral gummies as a treatment for Ebola in DR Congo is set to begin soon.
NNVC - NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
NNVC - As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
NanoViricides, Inc. (NYSE: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bund